Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TT8ZLTI)

• DTT Name: Programmed cell death 1 ligand 1 (PD-L1) DTT Info
• Gene Name: CD274

Molecule-Related Drug & Molecule List

6 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Atezolizumab	DMMF8U0	Non-small-cell lung cancer	2C25	Approved	[1]
Avelumab	DMSZLJR	Merkel cell carcinoma	2C34	Approved	[2]
Bavencio	DMU9C8F	Merkel cell carcinoma	2C34	Approved	[3]
Durvalumab	DM4PVDY	Urothelial carcinoma	2C92.0	Approved	[4]
RG-7446	DM69XMQ	Urothelial carcinoma	2C92.0	Approved	[5]
Sugemalimab	DMH5YQ3	Non-small-cell lung cancer	2C25	Approved in China	[6]

35 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
A167	DME00MM	Nasopharyngeal carcinoma	2B6B	Phase 3	[7]
CS1001	DMSY0NE	Non-small-cell lung cancer	2C25	Phase 3	[8]
KN046	DMSDBPG	Non-small-cell lung cancer	2C25.Y	Phase 3	[9]
MEDI4736	DM5X849	Solid tumour/cancer	2A00-2F9Z	Phase 3	[10]
MPDL-3280A	DM9K3LM	Melanoma	2C30	Phase 3	[11]
Bintrafusp alfa	DMB9LRJ	Non-small-cell lung cancer	2C25	Phase 2	[12]
CX-072	DMVZT2I	Advanced malignancy	2A00-2F9Z	Phase 2	[13]
INCB86550	DMJN9PU	Solid tumour/cancer	2A00-2F9Z	Phase 2	[14]
KN035	DMKLMG6	Pleomorphic sarcoma	2B54	Phase 2	[15]
M7824	DMJCULI	Solid tumour/cancer	2A00-2F9Z	Phase 2	[16]
Pidilizumab	DMMO46E	Diffuse large B-cell lymphoma	2A81	Phase 2	[17]
BGB-A333	DM5VG6S	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[18]
GS-4224	DM1GE67	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[19]
NM21-1480	DMDNJP5	Advanced solid tumour	2A00-2F9Z	Phase 1/2	[20]
A337	DMXWFP2	Aggressive cancer	2A00-2F9Z	Phase 1	[7]
ALPN-202	DMTD4EF	Solid tumour/cancer	2A00-2F9Z	Phase 1	[21]
Anti-PD-L1	DM0UL47	Human immunodeficiency virus-1 infection	1C62	Phase 1	[22]
Anti-PD-L1 CSR T cells	DMWIJL1	Glioblastoma multiforme	2A00.0	Phase 1	[23]
BMS-986189	DMXU5FK	N. A.	N. A.	Phase 1	[15]
C-Met/PD-L1 CAR-T Cell	DMHBNKP	Hepatocellular carcinoma	2C12.02	Phase 1	[24]
CA-170	DMOUHR4	Lymphoma	2A80-2A86	Phase 1	[16]
Cosibelimab	DMULBZM	Non-small-cell lung cancer	2C25	Phase 1	[25]
FAZ053	DM71HLX	Advanced cancer	2A00-2F9Z	Phase 1	[13]
FS118	DM0QH9K	Advanced cancer	2A00-2F9Z	Phase 1	[15]
GEN1046	DMEWRNZ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[26]
IBI318	DMB83V4	Non-small-cell lung cancer	2C25	Phase 1	[27]
INBRX-105	DM2FH10	Solid tumour/cancer	2A00-2F9Z	Phase 1	[28]
KD033	DMTYNRB	Solid tumour/cancer	2A00-2F9Z	Phase 1	[29]
LY3300054	DMOV2ML	Advanced malignancy	2A00-2F9Z	Phase 1	[16]
LY3415244	DM5QO1A	Solid tumour/cancer	2A00-2F9Z	Phase 1	[30]
MCLA-145	DM8CGUV	Lymphoma	2A80-2A86	Phase 1	[31]
MSB2311	DMH8VXE	Advanced malignancy	2A00-2F9Z	Phase 1	[15]
PD-L1 t-haNK	DMLJHM2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[32]
PF-07257876	DM0E2SW	Non-small-cell lung cancer	2C25	Phase 1	[33]
TAK-252	DM1AKNI	Solid tumour/cancer	2A00-2F9Z	Phase 1	[34]

2 Patented Agent(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMID30107136-Compound-Example1	DMY37VQ	Hepatitis	DB97.Z	Patented	[35]
PMID30107136-Compound-Example2	DM9HMB4	Hepatitis	DB97.Z	Patented	[35]

10 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CA-327	DMP5OSK	N. A.	N. A.	Investigative	[15]
PMID30247903-Compound-General structure10	DMOA1Y7	N. A.	N. A.	Investigative	[15]
PMID30247903-Compound-General structure12	DMA3ZPH	N. A.	N. A.	Investigative	[15]
PMID30247903-Compound-General structure5	DM7LUI2	N. A.	N. A.	Investigative	[15]
PMID30247903-Compound-General structure6	DMHQ6C3	N. A.	N. A.	Investigative	[15]
PMID30247903-Compound-General structure7	DM9QMA2	N. A.	N. A.	Investigative	[15]
PMID30247903-Compound-General structure8	DMLMYE0	N. A.	N. A.	Investigative	[15]
PMID30247903-Compound-General structure9	DMBR7A6	N. A.	N. A.	Investigative	[15]
YH010	DMA1T66	Aggressive cancer	2A00-2F9Z	Investigative	[36]
YH011	DM3JEEU	Aggressive cancer	2A00-2F9Z	Investigative	[37]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [2] Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. Cancer Immunol Res. 2015 Oct;3(10):1148-57.
• [3] ClinicalTrials.gov (NCT03403777) Avelumab in Refractory Testicular Germ Cell Cancer.. U.S. National Institutes of Health.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [5] PD-1 as a potential target in cancer therapy. Cancer Med. 2013 October; 2(5): 662-673.
• [6] Sugemalimab: First Approval. Drugs. 2022 Apr;82(5):593-599.
• [7] Clinical pipeline report, company report or official report of Klus Pharma
• [8] GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy. Transl Lung Cancer Res. 2020 Oct;9(5):2008-2015.
• [9] Clinical pipeline report, company report or official report of Alphamab Oncology.
• [10] National Cancer Institute Drug Dictionary (drug id 740856).
• [11] Targeted immunotherapy for non-small cell lung cancer. World J Clin Oncol. 2014 May 10; 5(2): 39-47.
• [12] Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF- and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial. J Thorac Oncol. 2020 Jul;15(7):1210-1222.
• [13] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [14] National Cancer Institute Drug Dictionary (drug name INCB086550).
• [15] Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.
• [16] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [17] PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J Immunother. 2011 Jun;34(5):409-18.
• [18] Clinical pipeline report, company report or official report of BeiGene.
• [19] Clinical pipeline report, company report or official report of Gilead Sciences.
• [20] Clinical pipeline report, company report or official report of Numab Therapeutics.
• [21] Clinical pipeline report, company report or official report of Alpine Immune Sciences.
• [22] Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012 Jun 28;366(26):2455-65.
• [23] ClinicalTrials.gov (NCT02937844) Pilot Study of Autologous Chimeric Switch Receptor Modified T Cells in Recurrent Glioblastoma Multiforme
• [24] ClinicalTrials.gov (NCT03672305) Clinical Study on the Efficacy and Safety of c-Met/PD-L1 CAR-T Cell Injection in the Treatment of HCC
• [25] Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
• [26] Clinical pipeline report, company report or official report of Genmab.
• [27] Clinical pipeline report, company report or official report of Innovent.
• [28] Clinical pipeline report, company report or official report of Inhibrx.
• [29] Clinical pipeline report, company report or official report of Kadmon.
• [30] Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors. Clin Cancer Res. 2021 May 15;27(10):2773-2781.
• [31] Clinical pipeline report, company report or official report of Merus.
• [32] ClinicalTrials.gov (NCT04050709) QUILT 3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers. U.S. National Institutes of Health.
• [33] ClinicalTrials.gov (NCT04881045) A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF PF-07257876 IN PATIENTS WITH ADVANCED OR METASTATIC TUMORS. U.S.National Institutes of Health.
• [34] Clinical pipeline report, company report or official report of Shattuck Labs.
• [35] A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
• [36] Clinical pipeline report, company report or official report of Biocytogen
• [37] Clinical pipeline report, company report or official report of Biocytogen